top of page
G3 Neuroendocrine Neoplasms (NEN) or High Grade
Grade 3 NET
Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs
BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors
Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms
Neuroendocrine Carcinoma (NEC)
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors
DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC
Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms
bottom of page